title: Severe familial hypercholesterolaemia: current and future management.
abstract: Familial hypercholesterolaemia is an inherited disorder, leading to accumulation of low-density lipoprotein (LDL) particles in plasma and premature cardiovascular disease. Although the phenotype of the rare homozygous form is always severe, the phenotypic expression of the common heterozygous familial hypercholesterolaemia can vary considerably. Beyond the magnitude of the LDL-cholesterol elevation and the type of mutation, additional genetic, metabolic and environmental cardiovascular risk factors lead to the substantial variations in the clinical manifestations and severity of atherosclerotic disease. Heterozygous familial hypercholesterolaemia is often under-diagnosed and under-treated, and there is an unmet need in terms of management of severe heterozygous forms. Homozygous and severe heterozygous familial hypercholesterolaemia should receive more intensive treatment and alternative therapeutic approaches are needed for these high-risk patients. In this article, we review the recommendations for diagnosis and treatment of severe familial hypercholesterolaemia and the agents currently available or under development.
authors.affiliation: Point médical, rond point de la Nation, Dijon, France. michelfarnier@nerim.net
authors.forename: Michel
authors.initials: M
authors.lastname: Farnier
authors.forename: Eric
authors.initials: E
authors.lastname: Bruckert
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D005544:Forecasting; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D009841:Oligonucleotides / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D000924:Anticholesteremic Agents; D009841:Oligonucleotides; C524142:mipomersen